Actualités et vidéos - AETERNA ZENTARIS INC.

Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders PR Newswire MILWAUKEE, June 7, 2024 MILWAUKEE , June 7, 2024 /PRNewswire/ -- Ademi LLP is investigating Aeterna ( Nasdaq: AEZS ) for possible breaches of fiduciary duty and other violations of law in its transaction with Ceapro . Click here to learn how to join our investigation: https://www.ademilaw.com/case/aeterna-zentaris-inc or call Guri Ademi toll-free at 866-264-3995....

Pharmanovia, une entreprise pharmaceutique mondiale qui commercialise de nouveaux médicaments et redonne un souffle, prolonge et étend le cycle de vie des médicaments existants, a annoncé aujourd'hui l'élargissement de son portefeuille d'endocrinologie grâce à un nouvel accord de licence pour GHRYVELIN™ (macimorelin), un nouveau médicament d'Aeterna Zentaris utilisé pour diagnostiquer le déficit en hormone de croissance chez l'adulte (AGHD). L'accord octroie les droits commerciaux...

- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the continuation of its Virtual Investor Spotlight Series to be held on Thursday, April 14, 2022. Access the full series of events here . Thursday, April 14, 2022 10:00 AM ET: CEO Spotlight Featuring Aeterna Zentaris (NASDAQ:AEZS) - Register Here Aeterna...

...

...

...

...

...

...

...

The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc. - AEZS PR Newswire NEWARK, N.J., Nov. 9, 2020 NEWARK, N.J. , Nov. 9, 2020 /PRNewswire/ -- The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP announce that the United States District Court for the District of New Jersey has approved the following announcement of a proposed class action settlement that would benefit purchasers of...

...

CHARLESTON, S.C., June 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of the Company’s common stock has been at $1.00 or greater for 10 consecutive trading days. On April 8, 2020, the...

CHARLESTON, S.C., June 04, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has received a positive decision from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Staff”), granting the Company’s request for an extension through October 5, 2020 to achieve compliance with...

CHARLESTON, S.C., May 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the results from its Annual General Meeting (“AGM”) held today, May 15, 2020. The individuals noted below were elected as Directors of the Company. The report on proxies provided by the Company’s transfer agent indicated the following:...

CHARLESTON, S.C., May 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced its Annual General Meeting (“AGM”) will be held on May 15, 2020 at 10:00 a.m. ET. Due to the impact of the COVID-19 pandemic, the meeting will be held virtually. Shareholders will not be able to attend the AGM in-person at a physical...

– First quarter marked by positive results from AEZS-130-P01 (“Study P01”), of macimorelin, providing clinical framework to advance pediatric investigation plan (“PIP”) for macimorelin as a growth hormone deficiency diagnostic – – Planned safety and efficacy study AEZS-130-P02 (“Study P02”) of macimorelin expected to commence in Q4 2020 – – Advancing ongoing business development discussions to secure a commercialization partner for macimorelin in Europe and other key global...

CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that on April 8, 2020, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum $1.00 per...

CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris will present at the April 2020 Virtual Investor Summit on Thursday, April 23, 2020 at 10:00 AM ET. A live audio webcast of the presentation will be available on...

– Modifications recommended for some key elements of planned safety and efficacy Study P02 – – Modifications to the outline of Study P02 requested to ensure a harmonized global study protocol complying with requirements from EMA as well as FDA – CHARLESTON, S.C., April 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic...